Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.

Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G.

J Med Chem. 2005 Apr 21;48(8):2892-905.

PMID:
15828828
2.

Discovery and development of purine-scaffold Hsp90 inhibitors.

Chiosis G.

Curr Top Med Chem. 2006;6(11):1183-91. Review.

PMID:
16842155
3.

Effectiveness of hsp90 inhibitors as anti-cancer drugs.

Xiao L, Lu X, Ruden DM.

Mini Rev Med Chem. 2006 Oct;6(10):1137-43. Review.

PMID:
17073714
4.

Recent advances in Hsp90 inhibitors as antitumor agents.

Messaoudi S, Peyrat JF, Brion JD, Alami M.

Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. Review.

PMID:
18855578
5.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
6.

Emerging Hsp90 inhibitors: from discovery to clinic.

Chiosis G, Rodina A, Moulick K.

Anticancer Agents Med Chem. 2006 Jan;6(1):1-8. Review.

PMID:
16475922
7.
8.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Chiosis G, Caldas Lopes E, Solit D.

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41. Review.

PMID:
16784024
9.
10.

Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Moser C, Lang SA, Stoeltzing O.

Anticancer Res. 2009 Jun;29(6):2031-42. Review.

11.

Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?

Isaacs JS.

Expert Opin Investig Drugs. 2005 Jun;14(6):569-89. Review.

PMID:
16004589
12.

Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.

Tsutsumi S, Neckers L.

Cancer Sci. 2007 Oct;98(10):1536-9. Epub 2007 Jul 23. Review.

13.

Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.

PetrikaitÄ— V, Matulis D.

Medicina (Kaunas). 2011;47(8):413-20. Epub 2011 Nov 18. Review.

14.
15.

Medicinal chemistry of Hsp90 inhibitors.

Drysdale MJ, Brough PA.

Curr Top Med Chem. 2008;8(10):859-68. Review.

PMID:
18673171
16.

Hsp90: a novel target for cancer therapy.

Solit DB, Rosen N.

Curr Top Med Chem. 2006;6(11):1205-14. Review.

PMID:
16842157
17.

Hsp90: the vulnerable chaperone.

Chiosis G, Vilenchik M, Kim J, Solit D.

Drug Discov Today. 2004 Oct 15;9(20):881-8. Review.

PMID:
15475321
18.

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

Workman P, Burrows F, Neckers L, Rosen N.

Ann N Y Acad Sci. 2007 Oct;1113:202-16. Epub 2007 May 18. Review.

PMID:
17513464
19.

Heat shock protein 90 inhibitors as therapeutic agents.

Gomez-Monterrey I, Sala M, Musella S, Campiglia P.

Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):313-36. Review.

PMID:
22338602
20.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

Supplemental Content

Support Center